Investment Highlights
  • First mover advantage in multi-billion dollar Mexico market and positioned for $750b market via export.

  • Strong, collaborative relationship with institutions leading the design of Mexico's cannabis regulatory framework.

  • Strong product suite: 53 new cannabinoid-based products in late-stages of development, ready for launch.

  • Large-scale GMP pharmaceutical production.

  • Execution skills and scientific expertise to capitalize on medicinal cannabis.

  • 20+ Years of pharma experience at the highest industry standards, domestically and internationally.